Previous 10 | Next 10 |
- Patients Treated with Tivozanib in TIVO-3 Study Demonstrated Over 20 Months Median DOR; OS Relative to Sorafenib Continues to Improve with Longer Follow-up - - Analysis of TEAEs in TIVO-3 Study Shows Longer Time to Onset and Fewer Dose Reductions for TEAEs for Tivozanib Comp...
– Study Achieved Primary Endpoint of mPFS in Patients Treated with Ficlatuzumab/Cetuximab (ERBITUX ® ) Combination – – 38% ORR, Including 13% CRs and 25% PRs, and Median PFS of 4.1 months Observed in HPV Negative Patients Treated with Ficlatuzumab...
AVEO Pharmaceuticals, Inc. (AVEO) Q1 2021 Earnings Conference Call May 11, 2021, 16:30 PM ET Company Participants Erick Lucera - Chief Financial Officer Michael Bailey - President and Chief Executive Officer Mike Ferraresso - Chief Commercial Officer Michael Needle - Chief Medical Officer Con...
AVEO Pharmaceuticals (AVEO): Q1 GAAP EPS of -$0.81 misses by $0.26.Revenue of $1.92M (+146.2% Y/Y) beats by $0.91M.AVEO believes that its $121.4 million in cash and cash equivalents as of March 31, 2021, along with net product revenues from the commercial launch of FOTIVDA in the United ...
– U.S. Commercial Launch Underway with Fully Deployed Sales Force Following FDA Approval of FOTIVDA ® (tivozanib) on March 10, 2021 – – FOTIVDA Net Product Revenue of $1.1 Million from Initial Distributor Orders in the Last Week of Q1; All Distrib...
AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will report first quarter 2021 financial results on Monday, May 10, 2021. AVEO’s management team will host a conference call and audio webcast at 4:30 p.m....
AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced the appointment of Kevin J. Cullen, M.D., to the Company’s Board of Directors. A widely recognized clinical oncologist with a specialty in head and neck cancer, Dr...
AVEO Oncology ([[AVEO]] +0.5%) announces that the National Comprehensive Cancer Network ((NCCN)) has updated its Clinical Practice Guidelines to include FOTIVDA (tivozanib) as a recommended regimen for subsequent therapy. FOTIVDA is an oral, next-generation vascular endothelial...
AVEO Oncology (Nasdaq: AVEO) today announced that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines to include FOTIVDA ® (tivozanib) as a recommended regimen for subsequent therapy. The subsequent therapy category follows the first-li...
AVEO Oncology (AVEO) has concluded a previously announced stock offering of 6.9M shares, including 900K shares purchased by underwriters.The company has earned gross proceeds of $55.2M.The proceeds will be used for working capital and general corporate purposes, including commercialization of...
News, Short Squeeze, Breakout and More Instantly...
AVEO Pharmaceuticals Inc. Company Name:
AVEO Stock Symbol:
NASDAQ Market:
SEOUL, South Korea, Jan. 19, 2023 (GLOBE NEWSWIRE) -- LG Chem, Ltd. (“LG Chem”) (KOSPI: 051910) today announced that it has completed its previously announced acquisition of AVEO Oncology (“AVEO”), a commercial stage, oncology-focused biopharmaceutical company committe...
BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced that at a special meeting of stockholders ...
BOSTON, Jan. 03, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, reminds all AVEO stockholders to vote before AVEO...